On the Origin of ATP Synthesis in Cancer.
Level 5 - mechanism / opinion, no new human data
Narrative review and theoretical biochemical framework with no primary human data.
PubMed 33251492 · doi:10.1016/j.isci.2020.101761
What was done
This paper is a narrative theoretical review examining bioenergetic mechanisms of ATP synthesis in cancer cells, focusing on oxidative phosphorylation impairment, glycolytic dynamics, and mitochondrial substrate-level phosphorylation.
What was found
The abstract reports no empirical clinical or experimental data. It outlines a mechanistic model where mitochondrial anomalies impair oxidative phosphorylation and dimeric pyruvate kinase M2 limits glycolytic ATP production. Under this framework, mitochondrial substrate-level phosphorylation via the glutamine-driven succinate-CoA ligase reaction compensates for ATP deficits to sustain the standard ATP hydrolysis free energy of -56 kJ/mole, driving proliferation and apoptotic resistance.
Why it matters
It highlights mitochondrial substrate-level phosphorylation as a potential critical driver of cancer cell energetics and rationalizes dual dietary or metabolic targeting of glucose and glutamine.
Limits
This is a conceptual review presenting mechanism-based reasoning without primary experimental measurements, sample sizes, or clinical trial data reported in the abstract.
Cited by
- supports Cancer cells drive dysregulated growth through the fermentation of glutamine via substrate-level phosphorylation in the mitochondrial matrix.